Toxicity of FED chemotherapy in non-small-cell lung cancer

K. S. Sridhar, J. Varki, E. Donnelly, E. Davila, P. Benedetto, S. Hilsenbeck, R. J. Thurer, R. K. Rao, G. Fountzilas, E. J. Beattie

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Twenty-eight patients with metastatic and/or recurrent non-small-cell lung cancer were treated with a new sequential combination of escalating doses of cisplatin (50, 75, and 100 mg/m2 IV x 1) followed by 5-FU infusion (40 mg/m2/hour x 72) and etoposide (80 mg/m2/day x 3). Three patients received concurrent external radiation therapy. Eleven of the 28 (39%) had a partial response to chemotherapy. Four others had a minor response. One partial responder became a complete responder by surgical excision of residual cancer. Median time to response was 6 weeks followed by a median response duration of 4 months. In responders, chemotherapy was discontinued at the time of maximal response. Median survival was 7 months. Chemotherapy was well tolerated with absence of leucopenia, thrombocytopenia, and nausea and vomiting in a majority of courses. The common toxicities were alopecia (100%), leucopenia (35%), nausea and vomiting (30%), and electrolyte imbalances (27%). Reversible nephrotoxicity, thrombocytopenia, anemia, mucositis, and diarrhea were infrequent. The response rate in stage IV was less than in stage III. The combination of moderate doses of cisplatin, 5-FU infusion, and etoposide provides a new palliative chemotherapy that is well tolerated with concurrent/sequential radiation therapy and may be useful in the multimodality treatment of non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)499-506
Number of pages8
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number6
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Toxicity of FED chemotherapy in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this